/PRNewswire/ — Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets,…Read More
Skyhawk Therapeutics Announces Expansion of its Global Pivotal FALCON-HD Clinical Trial for SKY-0515 in Huntington’s Disease to the United States, Canada and the United Kingdom
